Table 1. Demographic, radiographic, and echocardiographic data of control dogs and dogs with myxomatous mitral valve disease (MMVD) according to ACVIM stage

Variable	Control (n = 10)	Stage B1 (n = 10)	Stage B2 (n = 10)	Stage C (n = 5)
Age (years)	5.5 ± 3.1	12.2 ± 2.491)	10.2 ± 3.771)	12 ± 4.241)
Weight (kg)	11.4 ± 5.66	5.21 ± 2.491)	5.46 ± 2.531)	3.97 ± 1.811)
VHS	10.49 ± 1.4	10.19 ± 0.84	11.48 ± 0.942)	11.92 ± 1.633)
VLAS	1.88 ± 0.33	2.17 ± 0.21	2.52 ± 0.421)	2.84 ± 0.693)
LA/Ao ratio	1.31 ± 0.1	1.32 ± 0.18	1.82 ± 0.173)	2.08 ± 0.264)
LVIDDn	1.39 ± 0.17	1.41 ± 0.19	1.74 ± 0.223)	1.96 ± 0.263)
E peak (cm/s)	75.38 ± 15.83	70.91 ± 18.76	99.17 ± 22.893)	115.94 ± 44.523)
LAD (mm)	26.2 ± 3.56	24.53 ± 5.85	30.4 ± 5.792)	31.42 ± 6.992)
LADn	12.22 ± 1.1	14.65 ± 2.02	17.95 ± 2.093)	20.44 ± 2.684)

p<0.05, vs. control group.
p<0.05, vs. B1.
p<0.05, control group and B1.
p<0.05, control, B1, and B2 groups.
ACVIM, American College of Veterinary Internal Medicine; VHS, vertebral heart size; VLAS, vertebral left atrial size; LA/Ao ratio, left atrial-to-aortic ratio; LVIDDn, left ventricular end-diastolic diameter normalized to body weight; LAD, left atrial anteroposterior diameter; LADn, left atrial anteroposterior diameter normalized to body weight.